Completed PHASE4 INTERVENTIONAL 2-arm NCT00408512

Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study (stayondiur)

Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.

Sponsor: Agenzia Italiana del Farmaco

Conditions Essential Hypertension

Interventions Non thiazidic treatment thiazides

Updated 5 times since 2017 Last updated: Jun 24, 2011 Started: Dec 31, 2006 Primary completion: Dec 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00408512, this PHASE4 trial focuses on Essential Hypertension and remains completed. Sponsored by Agenzia Italiana del Farmaco, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agenzia Italiana del Farmaco
Federico II University

Data source: Federico II University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Napoli, Italy